AbCellera Biologics Inc vs Adecoagro SA — how do they compare? AbCellera Biologics Inc trades at $9.02 (market cap $2.85B), while Adecoagro SA trades at $9.47 (market cap $1.39B). The key difference: AbCellera Biologics Inc is far larger — about 2.1× Adecoagro SA's market cap, and Adecoagro SA pays a 3.07% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AGRO | |
|---|---|---|
Market Cap | $2.85B | $1.39B |
Sector | Health | Technology |
52-Week High | $9.76 | $15.25 |
52-Week Low | $2.78 | $7.13 |
Enterprise Value | $2.45B | $3.43B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
AGRO trades at $9.45, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported negative net income of -$8.35M for 2025 despite $1.43B revenue, though 2026 projections show potential profitability improvement. Recent acquisition of Caarapó Mill expands operational footprint while analyst consensus leans neutral with 50% hold ratings.
Outlook remains cautious with elevated P/E ratio of 536.67 offset by attractive P/B of 0.79. Key risks include commodity volatility and integration challenges from recent acquisitions. The stock presents value opportunity if 2026 profitability targets are achieved, but requires careful monitoring of earnings trajectory.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →